258 related articles for article (PubMed ID: 23510353)
1. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Barazzuol L; Jena R; Burnet NG; Meira LB; Jeynes JC; Kirkby KJ; Kirkby NF
Radiat Oncol; 2013 Mar; 8():65. PubMed ID: 23510353
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
4. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Lemasson B; Wang H; Galbán S; Li Y; Zhu Y; Heist KA; Tsein C; Chenevert TL; Rehemtulla A; Galbán CJ; Holland EC; Ross BD
Neoplasia; 2016 Feb; 18(2):82-9. PubMed ID: 26936394
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
[TBL] [Abstract][Full Text] [Related]
7. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
8. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Palma JP; Wang YC; Rodriguez LE; Montgomery D; Ellis PA; Bukofzer G; Niquette A; Liu X; Shi Y; Lasko L; Zhu GD; Penning TD; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Clin Cancer Res; 2009 Dec; 15(23):7277-90. PubMed ID: 19934293
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
10. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
12. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
13. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
[TBL] [Abstract][Full Text] [Related]
14. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Clarke MJ; Mulligan EA; Grogan PT; Mladek AC; Carlson BL; Schroeder MA; Curtin NJ; Lou Z; Decker PA; Wu W; Plummer ER; Sarkaria JN
Mol Cancer Ther; 2009 Feb; 8(2):407-14. PubMed ID: 19174557
[TBL] [Abstract][Full Text] [Related]
15. ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Yuan AL; Ricks CB; Bohm AK; Lun X; Maxwell L; Safdar S; Bukhari S; Gerber A; Sayeed W; Bering EA; Pedersen H; Chan JA; Shen Y; Marra M; Kaplan DR; Mason W; Goodman LD; Ezhilarasan R; Kaufmann AB; Cabral M; Robbins SM; Senger DL; Cahill DP; Sulman EP; Cairncross JG; Blough MD
PLoS One; 2018; 13(8):e0202860. PubMed ID: 30153289
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
[TBL] [Abstract][Full Text] [Related]
17. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
18. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
